Tuesday, May 20, 2025 4:08:10 PM
Too funny-this “news” almost 10 years ago:
Sunshine Biopharma Is Moving Forward With Its Development Plans for Adva-27a Anticancer Compound
“MONTREAL, QC--(Marketwired - Jan 20, 2016) - Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it is moving forward with its plans for the development of Adva-27a and to this end it has recently acquired all of the rights, title and interest in and to all worldwide patents for the Adva-27a anticancer compound. In addition, the Company is currently in discussions with several investment groups for the purposes of securing funding for Adva-27a development through Phase I clinical trials. Adva-27a has proven to be effective at killing Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells and Uterine Sarcoma cells (Results published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). The Company is planning Phase I clinical trials of Adva-27a on Pancreatic Cancer and, in parallel, Multidrug Resistant Breast Cancer patient volunteers to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).“
Sunshine Biopharma Is Moving Forward With Its Development Plans for Adva-27a Anticancer Compound
“MONTREAL, QC--(Marketwired - Jan 20, 2016) - Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it is moving forward with its plans for the development of Adva-27a and to this end it has recently acquired all of the rights, title and interest in and to all worldwide patents for the Adva-27a anticancer compound. In addition, the Company is currently in discussions with several investment groups for the purposes of securing funding for Adva-27a development through Phase I clinical trials. Adva-27a has proven to be effective at killing Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells and Uterine Sarcoma cells (Results published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). The Company is planning Phase I clinical trials of Adva-27a on Pancreatic Cancer and, in parallel, Multidrug Resistant Breast Cancer patient volunteers to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).“
Recent SBFM News
- Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R) • ACCESS Newswire • 06/01/2026 12:00:00 PM
- Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology • ACCESS Newswire • 05/29/2026 12:00:00 PM
- Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing • ACCESS Newswire • 05/28/2026 01:00:00 PM
- Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin • ACCESS Newswire • 05/21/2026 11:00:00 AM
- Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering • ACCESS Newswire • 05/19/2026 04:05:00 PM
- Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering • ACCESS Newswire • 05/18/2026 04:15:00 PM
- Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year • ACCESS Newswire • 04/06/2026 12:30:00 PM
- Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea • ACCESS Newswire • 10/28/2025 11:45:00 AM
- Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline • ACCESS Newswire • 10/20/2025 11:45:00 AM
- Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin • ACCESS Newswire • 10/16/2025 11:45:00 AM
- Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience • ACCESS Newswire • 10/14/2025 11:00:00 AM
- Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections • ACCESS Newswire • 10/09/2025 12:00:00 PM
